Epstein-Barr virus vaccine development: a lytic and latent protein cocktail.
Lockey, Timothy D; Zhan, Xiaoyan; Surman, Sherri; Sample, Clare E; Hurwitz, Julia L.
; 13: 5916-27, 2008 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-18508632
Prevention and treatment of papillomavirus-related cancers through immunization.
Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Immunogenic cell death in cancer therapy.
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
EBV oncogene N-LMP1 induces CD4 T cell-mediated angiogenic blockade in the murine tumor model.
Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.
Persistent low level Epstein-Barr virus DNAemia in childhood cancer survivors.
Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies.
Regulation of the latent-lytic switch in Epstein-Barr virus.
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment.